Welcome to our dedicated page for Exagen SEC filings (Ticker: XGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company focused on autoimmune disease testing, and its SEC filings provide detailed information on this business. As a Delaware corporation with securities registered under Commission File Number 001-39049, Exagen submits periodic and current reports to the U.S. Securities and Exchange Commission that describe its financial condition, operations, and risks as a provider of autoimmune diagnostics and autoimmune testing solutions.
On this page, you can review Exagen’s SEC filings, including current reports on Form 8-K that furnish press releases about quarterly and year-to-date financial results. For example, the company has used Form 8-K to report results for periods ended June 30 and September 30, including revenue, operating loss, net loss, adjusted EBITDA, and balance sheet data such as cash and cash equivalents, borrowings, and warrant liabilities. These filings also include discussions of non-GAAP measures like adjusted EBITDA and explanations of how management uses these metrics.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the broader filing set) typically contain more extensive disclosures about Exagen’s autoimmune testing business, its AVISE-branded portfolio, regulatory and reimbursement considerations, and risk factors related to its operations and market. Proxy materials can provide additional detail on governance and equity compensation.
Stock Titan’s tools surface Exagen’s filings as they are posted to EDGAR and add AI-powered summaries that explain key points in accessible language. Investors can quickly locate 10-K and 10-Q reports for a deeper view of revenue trends and operating metrics, and track Form 8-K disclosures related to financial results. Where applicable, insider transaction reports on Form 4 can also be accessed to see equity activity by Exagen’s officers and directors.
Exagen Inc. filed a current report to note that it has released its financial results for the three and nine months ended September 30, 2025. The company issued a press release on November 4, 2025, which is attached as Exhibit 99.1 and provides the detailed figures and commentary on its results of operations and financial condition.
The report clarifies that the earnings information and the press release are being furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other securities law filings unless specifically referenced.
Exagen Inc. (XGN) disclosed an insider transaction by its President and CEO, who is also a Director. On 10/16/2025, he sold 31,787 shares of common stock at $11.8161 per share, coded “S.”
According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding on the vesting and settlement of Restricted Stock Units, and it was not a discretionary transaction by the reporting person.
Following the transaction, the reporting person beneficially owned 714,427 shares directly, plus 40,401 shares indirectly held by spouse.
Jeffrey G. Black, Chief Financial Officer of Exagen Inc. (XGN), sold 20,466 shares of common stock on 09/02/2025 at a price of $9.79 per share to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units (RSUs). The Form 4 shows the transaction was a mandatory "sell-to-cover" required by the issuer and not a discretionary sale by the reporting person. After the sale, the reporting person beneficially owned 269,026 shares, held directly. The filing is signed by the reporting person on 09/04/2025.
Exagen Inc. reporting person Laurence W. Lytton discloses beneficial ownership of 216,840 shares of common stock, representing 1.0% of the outstanding class. The filing states Mr. Lytton has sole voting and sole dispositive power over these shares, with no shared authority reported.
The statement affirms the shares are not held to influence control of the issuer and the reporting person certifies the accuracy of the disclosure. The filing indicates the position is not part of any group and no other parties are identified as holding power over the securities.
RTW Investments, LP and Roderick Wong, M.D. filed Amendment No. 5 to a Schedule 13G reporting ownership in Exagen Inc. (Common Stock, CUSIP 30068X103). The Reporting Persons disclose beneficial ownership of 1,696,866 shares, representing 7.7% of the class based on 21,998,739 shares outstanding as of June 30, 2025, per the issuer's quarterly report filed July 29, 2025. The filing shows shared voting and shared dispositive power over these shares and no sole voting or dispositive power. The RTW Funds have the right to receive dividends or proceeds. The statement is signed on 08/14/2025 and is filed as a passive Schedule 13G amendment.
Exagen Inc. (XGN) 10-Q highlights for Q2 2025:
- Revenue: $17.2 M, up 14% YoY; six-month revenue $32.7 M (+11%). AVISE CTD accounted for 91% of sales.
- Profitability: Gross margin held at ~60% ($10.4 M). Operating loss was $2.6 M (flat YoY) but net loss widened to $4.4 M (-49 ¢ YoY) due to higher interest ($1.1 M) and a $0.4 M warrant fair-value loss. EPS was -$0.21 vs -$0.16.
- Cash flow & liquidity: Operating cash burn was $13.6 M. Cash & equivalents rose to $30.0 M (from $22.0 M at 12/24) after a $18.6 M May equity offering and a $25.0 M Tranche A draw under a new $75 M Perceptive Credit term loan. Minimum unrestricted-cash covenant is $3 M.
- Balance sheet: Total assets $58.8 M; shareholders’ equity improved to $21.0 M (was $9.5 M). Borrowings $22.3 M long-term and $0.7 M current; effective interest rate on Perceptive loan 16.2%.
- Warrants: 400 k warrants (exercise $5.27) issued; liability marked at $4.0 M. Up to 750 k more may vest with future draws.
- Customer & supplier risk: Customer A 23% of revenue; top three suppliers provided 92% of test consumables.
- Legal: DOJ qui tam case dismissed with prejudice in July 2025.
- Outlook: Management believes current cash funds operations ≥12 months but may seek additional capital to support growth and R&D pipeline.
Exagen Inc. (Nasdaq: XGN) filed a Form 8-K dated July 29, 2025. The filing is limited to the disclosure that, on the same date, the company released its unaudited financial results for the three- and six-month periods ended June 30, 2025.
Item 2.02 – Results of Operations and Financial Condition: The related earnings press release is furnished as Exhibit 99.1. Because the information is furnished—not filed—it is expressly excluded from Section 18 liability and is not automatically incorporated by reference into other SEC filings.
Item 9.01 – Exhibits: 99.1 (Press Release dated July 29, 2025) and 104 (Cover Page iXBRL).
No additional material events, financial metrics, or strategic updates are included in this report.
Exagen Inc. (Nasdaq: XGN) has filed a Form S-3 shelf registration statement to cover the potential resale of up to 1,150,000 shares of common stock that may be issued upon exercise of a warrant granted to Perceptive Credit Holdings IV, LP. The warrant was issued as part of a senior secured delayed-draw term loan facility signed on 25 April 2025.
Key equity details
- Shares registered: 1,150,000, representing future dilution of roughly 6.3 % of the 18.3 million shares outstanding (FY-2024 10-K).
- Current market value (based on the 18 June 2025 close of $7.36): ≈ $8.5 million.
- Vesting schedule: 400 k shares vested at closing; 150 k each vest on Tranche B & C borrowings; 450 k vest on Tranche D.
- Proceeds: Company receives no proceeds from stockholder resales; it will receive cash only if the warrant is exercised for cash.
Debt financing structure
- Total commitment: $75 million senior secured term loan (the “Perceptive Term Loan Facility”).
- Draws: $25 m funded (Tranche A); additional Tranches B ($10 m), C ($10 m) and D ($30 m) available through Mar-2027, subject to revenue and business-development milestones.
- Interest: greater of Term SOFR or 4.75 % plus 7 % margin (effective floor rate 11.75 %).
- Maturity: 25 April 2030; interest-only during the term with principal due at maturity.
The filing grants Perceptive registration rights, allowing it to sell shares from time to time via multiple distribution methods. While Exagen strengthens liquidity through the credit facility, investors should weigh potential dilution and elevated leverage at a double-digit interest rate. The company will also bear all registration expenses, and secondary selling could pressure the share price.
Strategic context
Exagen’s core business focuses on its AVISE® rheumatology diagnostics platform. Management seeks non-dilutive capital to fund growth, yet the warrant structure nonetheless introduces share issuance risk. The extended six-year draw window and five-year interest-only period provide operating flexibility but lock the company into a high-cost debt instrument until 2030.